Wisconsin Alumni Research Foundation

Pharmaceuticals & Vitamin D
Pharmaceuticals Vitamin D
Preparations and Uses of an Endogenous Aryl Hydrocarbon Receptor
WARF: P01315US

Inventors: Margaret Clagett-Dame, Hector DeLuca, Richard Peterson, Jiasheng Song, Rafal Sicinski, William Westler

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a novel endogenous AhR ligand.
Overview
The aryl hydrocarbon receptor (AhR) is a ligand-inducible transcription factor that mediates a broad spectrum of biological processes. It is a member of the emerging bHLH/PAS (basic Helix-Loop-Helix/Pas-Arnt-Sim) super family of transcription factors. Many synthetic chemical agents are recognized ligands for AhR, but endogenous AhR ligands have not yet been identified.
The Invention
UW-Madison researchers have identified a novel endogenous AhR ligand, 2-(1`H-indole-3`-carbonyl)-thiazole-4-carboxylic acid methyl ester. This AhR ligand likely regulates cell growth and differentiation in a highly tissue-specific manner, and may also exhibit responses similar to those caused by some of the known AhR ligands. Determining the normal physiological function(s) of this ligand should provide important new information on the mechanism of AhR-mediated biological responses. In addition, this endogenous AhR ligand and its various analogs should be useful for a wide variety of therapeutic applications.
Applications
  • Reducing body weight of humans or animals
  • Treating transplant rejection, autoimmune diseases, immunodeficiency disorders or chronic infectious diseases
  • Treating breast cancer or osteoporosis
  • Treating prostate cancer, male pattern baldness, virilizing syndromes in women or precocious puberty in boys
  • Inhibiting sex drive in men who are sex offenders
  • Treating pulmonary disorders such as chronic obstructive pulmonary disease, asthma, emphysema, bronchitis, RQ mismatch or acute pulmonary dysfunction
  • Controlling angiogenesis in invasive cancer
Key Benefits
  • May increase understanding of the physiological functions of the AhR system and the potential therapeutic benefits this system may offer
  • Ligand and its analogs may be administered orally or parenterally.
Additional Information
For More Information About the Inventors
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847

WARF